Лучшие больницы для «Balloon Mitral Valvuloplasty» в Дубай, ОАЭ
3 больниц по направлению «Кардиоторакальная и сосудистая хирургия» представлены в нашей сети в ОАЭ, Дубай, с аккредитацией Hospital Certificates of Services, JCI.
На этой странице перечислены больницы направления «Кардиоторакальная и сосудистая хирургия» (включая Balloon Mitral Valvuloplasty) в Дубай, ОАЭ, включая Burjeel Hospital for Advanced Surgery Dubai, Kings College Hospital Dubai, Aster Hospital Dubai.
Спросите нас о «Balloon Mitral Valvuloplasty» в Дубай, ОАЭ
Оставьте свои данные — наша команда координации свяжется с вами и расскажет о следующих шагах.
Сравните 3 аккредитованных больниц (Кардиоторакальная и сосудистая хирургия) в Дубай, ОАЭ
Рекомендуем🇦🇪 Burjeel Hospital for Advanced Surgery Dubai
Больница занимает 1-е место в этом списке по указанному рейтингу (4.5/5, 1 отзывов).
🇦🇪 Kings College Hospital Dubai
Больница занимает 2-е место в этом списке по указанному рейтингу (4.5/5, 1 отзывов).
🇦🇪 Aster Hospital Dubai
Больница занимает 3-е место в этом списке по указанному рейтингу (4.5/5, 1 отзывов).
Как мы выбираем эти больницы
Больница появляется на этой странице, если направление «Кардиоторакальная и сосудистая хирургия» указано среди её специализаций и она находится в Дубай, ОАЭ. Сортировка — по указанному рейтингу (по убыванию), без редакционного рейтинга «лучших».
Как выбрать лучшую больницу для «balloon mitral valvuloplasty» в Дубай, ОАЭ?
Выбор подходящей больницы для «balloon mitral valvuloplasty» — важное решение в вашем пути лечения. Вот на что стоит обратить внимание:
Международная аккредитация
Ищите больницу с международной аккредитацией, например JCI или NABH — см. отметки аккредитации у каждой больницы ниже.
Специализация
Убедитесь, что в больнице есть отделение, специализирующееся на «Кардиоторакальная и сосудистая хирургия», а не только общая помощь.
Мощность и опыт
Количество коек и год основания, указанные ниже, отражают масштаб и операционный опыт больницы.
Прозрачность стоимости
Запросите детализированную смету перед поездкой — используйте наш калькулятор стоимости для первичной оценки.
Что нужно знать о процедуре «Balloon Mitral Valvuloplasty»
Balloon Mitral Valvuloplasty (BMV), also known as Percutaneous Transvenous Mitral Commissurotomy (PTMC), is a minimally invasive, catheter-based procedure used to open a narrowed mitral valve (mitral stenosis), restoring normal blood flow across the valve without open-heart surgery — with documented procedural success rates exceeding 90–95% in appropriately selected patients at high-volume centers. International patients travel to India and the UAE for this procedure because both destinations offer world-class interventional cardiology infrastructure, JCI and NABH/DHA-accredited hospitals, and access to experienced operators who perform hundreds of BMV cases annually. GAF Healthcare connects patients with these elite centers, managing the entire medical journey from remote diagnosis through post-procedural discharge planning. Hospital Stay: 2–4 days • Total Stay in Country (Fit-to-Fly): 1–2 weeks • Success Rate: 90–95%
Clinical Overview
Mitral stenosis (MS) is a valvular heart disease characterized by progressive thickening, calcification, and fusion of the mitral valve leaflet commissures, reducing the normal mitral valve area (MVA) from approximately 4–6 cm² to below 1.5 cm² in hemodynamically significant disease. This obstruction elevates left atrial pressure, causing pulmonary venous hypertension, dyspnea on exertion, atrial fibrillation, hemoptysis, and — in advanced cases — right heart failure and pulmonary arterial hypertension. The dominant etiology worldwide remains rheumatic heart disease, making mitral stenosis disproportionately prevalent in South Asia, the Middle East, Africa, and Latin America — populations that constitute a significant portion of GAF Healthcare's international patient base. The physiological burden of mitral stenosis is quantified using Doppler echocardiography, which measures the mean transmitral gradient, pressure half-time (PHT), mitral valve area by planimetry, and the degree of pulmonary hypertension. The Wilkins Score (also called the Massachusetts General Hospital Score) is the most widely validated echocardiographic scoring system used to determine BMV candidacy: it grades leaflet mobility, thickening, calcification, and subvalvular disease on a scale of 1–4 per category (maximum score 16). A Wilkins Score ≤8 is associated with excellent BMV outcomes, while scores of 9–11 require individualized assessment and scores above 12 predict suboptimal results. The current standard of care for symptomatic mitral stenosis with favorable valve morphology is Percutaneous Balloon Mitral Valvuloplasty (BMV/PTMC), recommended as a Class I intervention in guidelines published by the American College of Cardiology/American Heart Association (ACC/AHA 2020) and the European Society of Cardiology (ESC 2021). In centers of excellence — including several JCI and NABH-accredited hospitals in India and JCI/DHA-accredited hospitals in Dubai and Abu Dhabi — BMV delivers immediate, durable relief from obstruction, with freedom from re-intervention rates exceeding 80% at 5 years in optimal morphology patients. Surgical mitral commissurotomy or mitral valve replacement remains reserved for patients with unfavorable anatomy, significant mitral regurgitation, or left atrial thrombus not amenable to anticoagulation.
Who is a Candidate?
• ELIGIBLE PATIENTS (Indications for BMV): • Symptomatic mitral stenosis (NYHA Class II–IV) with mitral valve area (MVA) ≤1.5 cm² and favorable valve morphology (Wilkins Score ≤8) • Asymptomatic severe mitral stenosis (MVA ≤1.0 cm²) with evidence of pulmonary hypertension (PASP >50 mmHg at rest) or new-onset atrial fibrillation • Patients in whom surgical risk is prohibitively high due to comorbidities (e.g., advanced COPD, severe pulmonary hypertension, elderly patients) • Pregnant patients with severe, symptomatic mitral stenosis refractory to medical therapy (BMV is the preferred intervention given avoidance of cardiopulmonary bypass and its associated fetal risks) • Patients with moderate MS and significant symptoms disproportionate to valve area, confirmed on exercise stress echocardiography showing a rise in mean gradient >15 mmHg or PASP >60 mmHg during exertion • REQUIRED PRE-PROCEDURAL DIAGNOSTICS: • Transthoracic Echocardiography (TTE): MVA by planimetry and PHT, Wilkins Score, degree of MR, PASP, LV/RV function • Transesophageal Echocardiography (TEE): Mandatory to exclude left atrial appendage (LAA) thrombus before the procedure • 12-Lead ECG: Rhythm assessment, atrial fibrillation burden • Chest X-Ray: Left atrial enlargement, pulmonary vascular congestion, Kerley B lines • Complete Blood Count, Coagulation Profile (PT/INR/aPTT), Renal Function, Liver Function Tests • Cardiac Catheterization (selective): Right and left heart hemodynamic assessment when non-invasive data is discordant or pulmonary hypertension severity needs quantification • Anti-Streptolysin O (ASO) titer and throat culture: To assess for active rheumatic activity requiring prophylaxis optimization • CONTRAINDICATIONS (Absolute and Relative): • Left atrial or left atrial appendage thrombus on TEE (absolute — procedure must be deferred until thrombus resolves with therapeutic anticoagulation, typically 3–6 months of warfarin with repeat TEE) • Moderate-to-severe mitral regurgitation (MR grade ≥2+/4+) — BMV carries a risk of worsening MR and surgical referral is preferred • Wilkins Score >12 — predicts suboptimal commissural splitting and increased MR risk • Severe bicommissural calcification (symmetric calcification prevents effective leaflet splitting) • Concomitant severe aortic or tricuspid valvular disease requiring surgical correction • Active infective endocarditis • Significant IAS (interatrial septal) abnormality that precludes safe transseptal puncture (e.g., prior ASD closure with device) • Severe, irreversible pulmonary hypertension with fixed pulmonary vascular resistance (a relative contraindication — specialist assessment required)
Treatment Options & Approaches
STANDARD TECHNIQUE — INOUE BALLOON TECHNIQUE: The Inoue technique is the global gold standard for BMV, accounting for the overwhelming majority of procedures performed worldwide. Under fluoroscopic and echocardiographic guidance, the interventional cardiologist gains femoral venous access and advances a catheter to the right atrium. Transseptal puncture using a Brockenbrough needle and Mullins sheath is performed under biplane fluoroscopy and/or intracardiac or transesophageal echocardiographic guidance to cross the interatrial septum safely at the fossa ovalis. The Inoue balloon — a unique self-positioning, pressure-extensible latex balloon with three distinct diameter stages (distal, equatorial, proximal) — is advanced across the mitral valve. Sequential inflation begins with the distal portion anchoring the balloon in the subvalvular apparatus, followed by full inflation at the mitral annulus level, delivering a precisely controlled commissurotomy. The target balloon diameter is calculated using the formula: balloon diameter (mm) = patient height (cm) / 10 + 10, with stepwise dilation under careful hemodynamic and echocardiographic monitoring. Procedural success is defined as an MVA ≥1.5 cm² with MR no greater than grade 2+/4+. ADVANCED TECHNIQUE — REAL-TIME 3D TRANSESOPHAGEAL ECHOCARDIOGRAPHY (RT-3D TEE) GUIDANCE: Leading centers in India (Mumbai, Chennai, Delhi) and the UAE (Dubai, Abu Dhabi) now perform BMV under real-time 3D TEE guidance, which provides superior visualization of the transseptal puncture site, balloon positioning relative to commissures, and immediate post-dilation assessment of commissural splitting and MR grade. This approach significantly reduces fluoroscopy time and radiation exposure, and is particularly valuable in patients with complex anatomy, prior commissurotomy, or pregnancy. ADVANCED TECHNIQUE — INTRACARDIAC ECHOCARDIOGRAPHY (ICE)-GUIDED BMV: ICE-guided BMV eliminates the need for general anesthesia (which is otherwise required for TEE guidance), allowing the procedure to be performed under conscious sedation alone. An ICE catheter (typically 8 Fr, 64-element phased array) is positioned in the right atrium to guide transseptal puncture and monitor balloon positioning. This approach is increasingly adopted in high-volume centers and is associated with shorter procedure times and improved patient comfort. DOUBLE-BALLOON TECHNIQUE: The double-balloon technique (using two separate balloon catheters advanced across the mitral valve) was the predecessor to the Inoue technique. It is now largely superseded by the Inoue balloon but may be used in specific anatomical scenarios where larger effective balloon dilating areas are required. MEDICAL THERAPY (ADJUNCTIVE AND PRE-PROCEDURAL): Pre-procedure optimization includes rate control for atrial fibrillation (beta-blockers such as metoprolol succinate or ivabradine in selected cases; non-dihydropyridine calcium channel blockers as alternatives), therapeutic anticoagulation with warfarin (target INR 2.5–3.5) for at least 3 months prior if LAA thrombus risk is elevated, and diuretics (furosemide ± spironolactone) for pulmonary congestion management. Rheumatic fever prophylaxis with benzathine penicillin G continues lifelong or until age 40 (whichever is longer) per current guidelines. Post-procedure anticoagulation strategy is individualized based on rhythm and procedural outcome. SURGICAL ALTERNATIVES (when BMV is not feasible): Open Surgical Mitral Commissurotomy (OSMC) via median sternotomy with cardiopulmonary bypass remains an option for patients with unfavorable anatomy. Minimally invasive right mini-thoracotomy approaches are available at select high-volume centers. Mitral Valve Replacement (MVR) with a mechanical prosthesis (St. Jude Medical, On-X) or biological bioprosthesis is the definitive surgical option for patients with concomitant severe MR, heavily calcified valves, or restenosis after prior BMV, with robotic-assisted MVR now available at select Indian and UAE centers for eligible patients.
Восстановление
PHASE 1 — REMOTE EVALUATION (2–4 weeks before travel): The patient's journey begins with GAF Healthcare's remote medical review. The patient submits recent echocardiography reports, ECG, chest X-ray, blood work, and clinical history through GAF Healthcare's secure digital platform. A GAF-affiliated interventional cardiologist reviews the data, calculates the Wilkins Score, assesses MVA, and determines BMV candidacy. A personalized treatment plan, cost estimate, and hospital recommendation are issued within 48–72 hours. PHASE 2 — ARRIVAL AND PRE-PROCEDURAL WORKUP (Day 1–2): On arrival, the patient is received by a GAF Healthcare coordinator at the airport and transferred to the partner hospital. Day 1 involves outpatient consultations, repeat TTE (to confirm baseline hemodynamics), TEE (to definitively exclude LAA thrombus), 12-lead ECG, complete blood panel, and coagulation profile. If the patient has been on warfarin, INR is checked; if therapeutic anticoagulation was used to resolve LAA thrombus, this TEE confirms resolution. Anesthesia consultation is completed. Consent discussion includes specific risks of transseptal puncture, balloon-induced MR, pericardial tamponade, and stroke. PHASE 3 — THE PROCEDURE (Day 2 or 3, approximately 60–120 minutes): The procedure is performed in a dedicated cardiac catheterization laboratory under fluoroscopic and echocardiographic guidance. The patient is positioned supine, and femoral venous access is obtained under local anesthesia with conscious sedation (or general anesthesia if TEE guidance is used). Transseptal puncture is performed, the Inoue balloon is advanced across the mitral valve, and stepwise dilation is performed. After each inflation, the interventionalist evaluates MVA by echo and assesses MR grade. The procedure concludes when target MVA is achieved (≥1.5 cm²) without significant MR increase. Total procedural time is typically 60–120 minutes. Hemostasis is achieved with manual compression or a vascular closure device at the femoral access site. PHASE 4 — IMMEDIATE POST-PROCEDURAL MONITORING (Day 2–4): The patient is transferred to a monitored cardiac care unit (CCU) or high-dependency unit (HDU) for 12–24 hours. Continuous ECG monitoring, pulse oximetry, and hemodynamic assessment are maintained. A post-procedural TTE is performed within 24 hours to confirm MVA improvement, assess MR severity, and rule out pericardial effusion. If the patient is in sinus rhythm, anticoagulation strategy is reassessed. If in persistent atrial fibrillation, therapeutic anticoagulation (warfarin or a DOAC as per electrophysiology guidance) is continued. The femoral access site is assessed for hematoma or vascular complications. Diuretics are adjusted based on fluid balance. The patient is mobilized to sitting on Day 1 post-procedure and walking by Day 2. PHASE 5 — HOSPITAL DISCHARGE (Day 3–4): Discharge criteria include: hemodynamic stability, echocardiographic confirmation of adequate MVA, no significant MR, no pericardial effusion, and intact femoral access site. A detailed discharge summary, medication reconciliation sheet (including anticoagulation plan, rhythm medications, rheumatic fever prophylaxis), and follow-up echocardiography schedule (at 1 month, 6 months, and annually) are provided. GAF Healthcare coordinates the discharge paperwork and arranges the post-discharge accommodation. PHASE 6 — POST-DISCHARGE RECOVERY AND FIT-TO-FLY WINDOW (Days 5–14): Most patients are fit for light activity within 3–5 days of the procedure. The femoral access site requires 5–7 days for complete skin healing. International air travel is safe after 7–14 days, provided the patient is hemodynamically stable, there is no significant residual MR, and no thromboembolic or access-site complications are present. GAF Healthcare arranges a clinical review on Day 7–10, including a repeat TTE and INR check (if on warfarin), to formally clear the patient for travel. Patients requiring anticoagulation receive a medical letter and sufficient medication supply for their home journey. RECOVERY MILESTONES: • Day 1 post-procedure: Sitting up, liquid diet, ECG monitoring • Day 2: Ambulation in room, solid diet, routine observations • Day 3–4: Hospital discharge • Day 5–7: Light daily activities at accommodation (walking, self-care) • Day 7–10: Clinical review, TTE, INR check, fit-to-fly assessment • Week 2–4: Return to sedentary work (remote work possible by week 2) • Month 1: Cardiology follow-up (can be done with home cardiologist with reports forwarded to GAF Healthcare) • Month 3–6: Repeat echocardiography to confirm sustained MVA improvement
Возможные риски
Balloon Mitral Valvuloplasty is a minimally invasive procedure with a well-established safety profile at high-volume centers, but patients must be counseled on specific procedural and post-procedural risks. The most clinically significant complication is acute severe mitral regurgitation (MR), occurring in approximately 2–4% of cases, caused by commissural tearing extending into the leaflet body or chordal rupture; severe MR may necessitate urgent surgical mitral valve repair or replacement. Transseptal puncture carries a small risk of cardiac perforation and hemopericardium (pericardial tamponade) in approximately 0.5–1% of cases, which is managed with pericardiocentesis and, rarely, surgical drainage. Thromboembolic events — including stroke or transient ischemic attack — occur in approximately 0.5–3% of patients, most commonly in those with pre-existing atrial fibrillation, inadequate anticoagulation, or an undetected LAA thrombus; this underscores the mandatory role of TEE prior to the procedure. Residual atrial septal defect (ASD) at the transseptal puncture site is common immediately post-procedure but closes spontaneously in the majority of patients within 6 months and is rarely hemodynamically significant. Femoral access-site complications (hematoma, pseudoaneurysm, arteriovenous fistula) occur in less than 1% of cases at experienced centers using ultrasound-guided access. Procedural failure — defined as inability to achieve MVA ≥1.5 cm² or the development of significant MR — occurs in approximately 5–10% of cases, more commonly with unfavorable Wilkins scores or heavily calcified valves, and necessitates referral for surgical management. Mitral restenosis (MVA falling below 1.5 cm² on follow-up) occurs in approximately 20–40% of patients at 5–10 years and may require repeat BMV or surgical intervention. All GAF Healthcare partner hospitals maintain on-site cardiac surgery backup for emergent surgical rescue, which is an absolute quality standard for any center performing BMV.
Почему GAF Healthcare
GAF Healthcare provides a comprehensive, end-to-end non-medical support infrastructure designed to eliminate logistical complexity for international patients and their families. VISA ASSISTANCE — INDIA: GAF Healthcare facilitates the Indian e-Medical Visa (eMV) application for patients traveling to India for BMV. The e-Medical Visa permits a stay of up to 60 days (extendable) and allows one accompanying attendant on a separate e-Medical Attendant Visa. GAF Healthcare provides the official medical invitation letter from the treating hospital, which is a mandatory document for the visa application. Processing typically takes 3–5 business days through the Indian government's online portal. VISA ASSISTANCE — UAE: Patients traveling to Dubai or Abu Dhabi for BMV benefit from the UAE's extensive visa-on-arrival program, which covers over 50 nationalities with free entry for stays up to 90 days. For nationalities requiring a prior visa, GAF Healthcare coordinates medical visa facilitation through the partner hospital's international patient services department, which is accredited under Dubai Health Authority (DHA) and Department of Health Abu Dhabi (DOH) frameworks. UAE medical visas are typically issued within 5–7 business days. AIRPORT TRANSFERS: Dedicated, air-conditioned private transfers are arranged for all arriving patients between the international airport and the hospital (for direct admission) or designated accommodation. Transfer vehicles are equipped to accommodate patients with dyspnea or mobility limitations and are staffed by GAF Healthcare-trained patient coordinators. DEDICATED MEDICAL INTERPRETERS AND PATIENT COORDINATORS: GAF Healthcare provides multilingual patient coordinators (fluent in Arabic, Hindi, French, Russian, Swahili, and other major languages) who accompany patients through consultations, procedure consents, discharge planning, and administrative processes. Medical interpretation during cardiology consultations and catheterization lab briefings is provided at no additional charge. ATTENDANT ACCOMMODATION: GAF Healthcare pre-arranges accommodation for one or two attending family members in partner-verified serviced apartments or hotels within close proximity to the treating hospital. Options range from budget-friendly to premium, with negotiated rates for GAF Healthcare patients. Accommodation is briefed on the patient's medical context to facilitate any emergency communication with the hospital team. POST-DISCHARGE SUPPORT: Following hospital discharge, GAF Healthcare coordinates the Day 7–10 clinical review appointment, echocardiogram scheduling, and INR monitoring (if applicable) at a partner diagnostic center. A digital copy of all medical records, echocardiography images, catheterization laboratory report, and discharge summary is provided in a format compatible with international medical record systems, facilitating seamless continuity of care with the patient's cardiologist at home. GAF Healthcare's medical team remains accessible via secure messaging for 30 days post-discharge for any clinical concerns.
Частые вопросы о процедуре «Balloon Mitral Valvuloplasty»
What is the cost of Balloon Mitral Valvuloplasty in India versus the UAE?
How long do I need to stay in India or the UAE before I am fit to fly home after Balloon Mitral Valvuloplasty?
What is the success rate of Balloon Mitral Valvuloplasty, and how long do results last?
Как GAF Healthcare помогает выбрать лучшую больницу для «balloon mitral valvuloplasty» в Дубай, ОАЭ
Найдите лучшие больницы для «balloon mitral valvuloplasty» в Дубай, ОАЭ
На этой странице представлено 3 больниц в Дубай, ОАЭ, чтобы вы могли сравнить аккредитацию и специализации в одном месте.
Поддержка, когда она нужна
Отправьте нам свои медицинские отчёты в WhatsApp или по email — наша медицинская команда изучит их и предложит больницу и план лечения.
Прозрачные, всё включено цены
Мы предоставляем единую детализированную смету, покрывающую расходы больницы и проживание — без скрытых платежей.
Организация визы, поездки и проживания
После выбора больницы мы помогаем оформить визовое приглашение, забронировать проживание рядом с больницей и организовать трансфер.
Хотите узнать примерную стоимость лечения? Используйте наш калькулятор стоимости для персональной оценки.
Частые вопросы о «Balloon Mitral Valvuloplasty» в Дубай, ОАЭ
Сколько больниц направления «Кардиоторакальная и сосудистая хирургия» представлено в Дубай, ОАЭ?
Как вы выбираете больницы для списка?
Сколько стоит лечение в Дубай, ОАЭ?
Следующий шаг
Отправьте нам свои медицинские отчёты — наша команда предложит больницу и план лечения для «Balloon Mitral Valvuloplasty» в Дубай, ОАЭ.
Свяжитесь с нами, если заметите неточность на этой странице.